Dr. Nianyong Chen 陈念永
Chief Physician
Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of tumors, focusing on radiotherapy, chemotherapy, molecular targeted therapy, and immunotherapy for head and neck, breast, lung, liver, rectal cancers, lymphoma, sarcoma, and pediatric tumors.
Dr. Chen is a Chief Physician and doctoral supervisor with a PhD and postdoctoral experience in the US. From 2002 to 2008, Dr. Chen conducted tumor and immunology research at the University of Virginia and other institutions. Previously served as Director of Radiotherapy at Sichuan Cancer Hospital.
Professional roles
- Director, Department of Head and Neck Oncology, West China Hospital
Name order: in Chinese the family name comes first (Chen Nianyong). Papers usually list the name as Nianyong Chen or Chen N.
Selected publications
77 papers on PubMed matched by name and affiliation; 25 as first or senior author since 2016. Most recent first- or senior-author papers:
- Head Neck, 2025 (senior author): Recurrent Patterns in Patients With Nasopharyngeal Caricinoma and Risks Leading to Inaccurate Delineation in Marginal Failure in the Era of Intensity-Modulated Radiotherapy. PubMed 39501710
- Int J Surg, 2025 (senior author): Extracorporeal membrane oxygenation as life-saving bridge for patients with airway obstruction caused by neck and chest tumors to salvage procedure: an in-depth review. PubMed 40053807
- Front Immunol, 2024 (senior author): Prognostic implications of tumor-infiltrating lymphocytes in non-small cell lung cancer: a systematic review and meta-analysis. PubMed 39372398
- J Nanobiotechnology, 2024 (senior author): The application of bacteria-nanomaterial hybrids in antitumor therapy. PubMed 39227831
- Front Immunol, 2024 (senior author): Corrigendum: Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer. PubMed 39034994
- Cancer Sci, 2024 (senior author): YTHDC1-dependent m6A modification modulated FOXM1 promotes glycolysis and tumor progression through CENPA in triple-negative breast cancer. PubMed 38566554
- Cancer Med, 2024 (senior author): Long-term outcomes of metastasis-directed stereotactic body radiation therapy in metastatic nasopharyngeal carcinoma. PubMed 38148586
- Head Neck, 2023 (senior author): First-line immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: An updated network meta-analysis and cost-effectiveness analysis. PubMed 37435624
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion